Skip to main content
MAYNE PHARMA GROUP LIMITED logo

MAYNE PHARMA GROUP LIMITED — Investor Relations & Filings

Ticker · MYX ISIN · AU000000MYX0 LEI · 549300VIRDEN0N4MJG59 ASX Manufacturing
Open in API
Filings indexed 1,121 across all filing types
Latest filing 2017-02-23 Interim / Quarterly Rep…
Country AU Australia
Listing ASX MYX

About MAYNE PHARMA GROUP LIMITED

https://www.maynepharma.com

Mayne Pharma Group Limited is a specialty pharmaceutical company focused on the development and commercialization of branded and generic medicines. The company operates through specialized segments including Women's Health and Dermatology. Its Women's Health portfolio features innovative contraceptive solutions, while the Dermatology division provides a broad range of treatments for various skin conditions. Beyond its product portfolio, the company provides contract development and manufacturing services (CDMO), leveraging proprietary drug delivery technologies to produce complex oral and topical dosage forms. The organization focuses on high-growth specialty markets, aiming to deliver differentiated therapeutic options and improve patient outcomes through technical excellence and strategic commercialization.

Recent filings

Filing Released Lang Actions
2017 Half Year Investor Presentation 23 pages 1.8MB
Interim / Quarterly Report Classification · 95% confidence The document is titled '1HFY17 Results Presentation' and dated 24 February 2017, indicating it is a presentation of half-year financial results. It contains detailed financial metrics for the first half of fiscal year 2017, including revenue, EBITDA, NPAT, and EPS, as well as operational highlights and segment performance. The document is about 15,000 characters long, which is substantial and contains substantive financial data and analysis. It is not a brief announcement or a certification letter. The content aligns with a comprehensive interim or quarterly financial report rather than a simple earnings release or investor presentation. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). H1 2017
2017-02-23 English
Appendix 3B 9 pages 723.9KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 3B' and is an announcement related to the issuance of new securities, specifically ordinary shares and employee options, by Mayne Pharma Group Limited. It includes detailed information about the class, number, issue price, purpose of the securities, and compliance with ASX listing rules. The document is structured as a formal notification to the Australian Securities Exchange (ASX) regarding a capital raising event and the application for quotation of additional securities. There is no financial performance data, management discussion, or audit information present. The content aligns with announcements about new share issues or capital changes rather than a full financial report or other categories. Therefore, the document fits the category of Share Issue/Capital Change (SHA). The document length (12,260 characters) and detailed content support a high confidence in this classification.
2017-02-19 English
Mayne Pharma launches Butalbital / APAP tablets in the US 1
Regulatory Filings Classification · 95% confidence The document is an ASX announcement about the launch of a pharmaceutical product in the United States by Mayne Pharma. It contains no financial statements, no regulatory certifications, no voting results, no management changes, no earnings data, and no detailed financial or strategic presentations. The document is relatively short (2516 characters) and serves as a corporate news release about a product launch. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Investor Presentation. It is a general regulatory announcement about business activity, best classified under Regulatory Filings (RNS).
2017-02-15 English
Mayne Pharma announces leadership changes 2 pages 107.5KB
Board/Management Information Classification · 95% confidence The document is an ASX announcement titled 'Mayne Pharma Announces Leadership Changes' dated 16 January 2017. It details appointments and changes in the company's leadership team, including new roles and responsibilities of executives. There is no financial data, regulatory filing references, or report attachments. The content focuses solely on management changes, which fits the category of Board/Management Information (MANG). The document length is about 5,496 characters, sufficient for a detailed announcement but not a full report. Therefore, the appropriate classification is MANG with high confidence.
2017-01-15 English
Mayne Pharma launches Amiodarone 100mg tablets 1 pa
Regulatory Filings Classification · 95% confidence The document is an ASX announcement about the launch of a pharmaceutical product (amiodarone tablets) in the United States by Mayne Pharma. It contains no financial statements, no regulatory filings, no voting results, no management or board changes, no earnings data, and no detailed financial or strategic presentation. The document is a straightforward corporate announcement about a product launch, which does not fit into categories like Annual Report, Earnings Release, or Investor Presentation. It is a general regulatory announcement about company activities, best classified under Regulatory Filings (RNS) as a miscellaneous announcement that does not fit other specific categories. The document length is short (2259 characters), and it is not a report publication announcement or certification. Therefore, the best classification is Regulatory Filings (RNS) with high confidence.
2017-01-12 English
Appendix 3B 9 pages 319.9KB
Capital/Financing Update Classification · 100% confidence The document is an Appendix 3B form, which is a standard Australian Securities Exchange (ASX) form used for announcements related to new issues of securities, applications for quotation of additional securities, and agreements related to these securities. It includes detailed information about the class and number of securities issued, issue price, purpose of the issue, and other related details. This type of document is specifically used to announce capital raising activities or changes in the capital structure of a company. It is not a financial report, earnings release, or management discussion, but rather a formal announcement of a capital/financing event. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and content confirm it is a full announcement, not just a brief notice or report publication announcement.
2017-01-11 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.